Navigation Links
Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication
Date:9/30/2013

NEW YORK, Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have begun a Phase I clinical research study of an investigational medication for Type 2 Diabetes Mellitus.  The study is being conducted to assess the safety and tolerability of multiple daily doses of the investigational medication over periods of up to 28 days.  

Diabetes has become one of the most prevalent diseases in the United States, with approximately 2 million people diagnosed each year.  The Center for Disease Control and Prevention estimates that roughly 35% of the population over the age of 20 is pre-diabetic.  For those over the age of 65, this number increases to 50%.  Clinilabs understands the growing need for treatment options in this field and is dedicated to helping sufferers combat the disease.  In response to the study award, Lead Recruiter Carrie Sorkin states: "Patients understand that clinical trials are a great way to find alternative treatment options for diabetes.  At Clinilabs, we have seen this first-hand through the great success we have had in our recruitment efforts."

Clinilabs is currently enrolling male and female volunteers, between the ages of 18 and 70, who have been diagnosed with Type 2 Diabetes Mellitus.  Any female patients interested in volunteering for this study must not be of childbearing potential. Patients must be on a stable treatment regimen for at least 4 weeks prior to screening and must have a body weight of above 45.0 kg.

Individuals in the Central New Jersey area who would like to participate can contact our dedicated call center at 212-994-4567 to prequalify.  Additional information may also be found by visiting www.cli
'/>"/>

SOURCE Clinilabs
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Leading evolutionary scientist to discuss how genome of bacteria has evolved
2. Worlds leading coral experts to gather in Australia
3. Putting plants online: 4 leading botanical gardens to create first online catalog of all plants
4. EMBO welcomes 55 leading life scientists as members
5. Leading statistician receives national citation award
6. Leading childhood asthma group supports federal asthma action plan to reduce disparities
7. BiOptix Participates in Leading Life Sciences Event BioWest 2012
8. Team including UC Riverside entomologist honored for research leading to healthier potato chips
9. Aware Enables Automated Delivery of Radiation Dose Information Through Integration With Leading Radiology Reporting System
10. Discovery of pathway leading to depression reveals new drug targets
11. Leading RSV researcher publishes work at Le Bonheur Childrens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... The Smart Card Alliance and the EMV Migration Forum.  ... the Smart Card Alliance Latin America (SCALA) Chapter provides ... and thought leaders promoting adoption of smart card technology. ...
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... PORTLAND, Ore. February 21, 2012. Log and lumber exports from ... 2011 compared to 2010, totaling 1,992 and 1,015 million board ... Station. Oregon and Washington are again the largest log exporter ... exported logs from west coast in 2011 increased by 54 ...
... is receptive to donating blood or other genetic material for ... University, Dallas. In what appears to be the first ... genetic biobank, the study surveyed 250 male and female undergraduate ... said they were willing to donate to a biobank, said ...
... PA, February 21, 2012 Using a noninvasive test on ... new algorithm for analysis, scientists can detect, with a high ... chromosomal abnormalities that cause Down syndrome and a genetic disorder ... scalable than other recently developed genetic screening tests and has ...
Cached Biology News:West coast log, lumber exports increased over forty percent in 2011 2Study finds college students willing to donate genetic material to biobanks for research 2Noninvasive method accurately and efficiently detects risk of Down syndrome 2Noninvasive method accurately and efficiently detects risk of Down syndrome 3
(Date:8/28/2015)... 28, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell ... ended June 30, 2015, corporate highlights, and near-term ... are available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment ...
(Date:8/28/2015)... ... ... initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake up ... the Fonz in a lab coat and Large Marge have been posted on the company’s ... , FireflySci is proud to be the only cuvette manufacturer is the world that has ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting ... business problems, is pleased to announce their ranking as one of the top 5000 ... the fastest-growing private companies across the nation. , “It is truly an honor to ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... Oct. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... covering interim results from a U.K. Phase ... advanced or,metastatic cancers is scheduled to be ... Molecular Targets and Cancer Therapeutics in,San Francisco. ...
... 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... letter of approval from the U.K. Medicines ... Clinical Trial Application (CTA) to begin,a clinical ... with cyclophosphamide, a chemotherapeutic agent as well ...
... Forecast Raised $.05 to $2.25 to $2.35., ST. LOUIS, Oct. 23 ... are to comparable periods in 2006):, -- Strongest Quarterly ... improved on prior quarters, performance, with reported quarterly ... matched the record high sales achieved in ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 2Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 2Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 4Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 5Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 6Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 7Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 8Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 9Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 10Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 11Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 12Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 13Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 14Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 15Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 16Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 17Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 18Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 19Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 20
... to PAX3 This protein is a ... of transcription factors. Members of the PAX ... and a paired-type homeodomain. These proteins play ... paired box gene 3 are associated with ...
Compact, portable device, seals 96 and 384 well plates with preset temperature optimised for Eppendorf heat sealing foils and films. Suitable for plates of different heights. AC input: 50/60 Hz230 V...
... BMP2 BMP2 belongs to the ... Bone morphogenic protein induces bone formation. ... the autosomal dominant disease of fibrodysplasia ... Synthetic peptide: PSDEVLSEFELRLLSM conjugated to ...
... thin foil heat sealing material is ... from a screw down heated lid), ... a useful method for sample retrieval. ... the existing seal. Ideal for compound ...
Biology Products: